Back
Zevra Therapeutics Quote, Financials, Valuation and Earnings
Invest. Do Good. Get Rewarded. Just $0.26/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
67
ZVRA
Zevra Therapeutics
Last Price:
9.33
Seasonality Move:
-0.11%
7 Day Trial
ALL ACCESS PASS
$
7
Zevra Therapeutics Price Quote
$9.33
Zevra Therapeutics Key Stats
Buy
67
Zevra Therapeutics (ZVRA)
is a Buy
Day range:
$9.31 - $9.53
52-week range:
$4.20 - $9.76
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
16.21
P/B ratio:
7.14%
Volume:
231.1K
Avg. volume:
606.1K
1-year change:
91.58%
Market cap:
$498M
Revenue:
$27.5M
EPS:
$-2.11
How Much Does Zevra Therapeutics Make?
-
How Much Are Zevra Therapeutics's Sales Annually?
ZVRA Revenues are $27.5M -
How Much Profit Does Zevra Therapeutics's Make A Year?
ZVRA net income is -$46M
Is Zevra Therapeutics Growing As A Company?
-
What Is Zevra Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.28% -
What Is Zevra Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Zevra Therapeutics Stock Price Performance
-
Did Zevra Therapeutics Stock Go Up Last Month?
Zevra Therapeutics share price went up by 12.95% last month -
Did ZVRA's Share Price Rise Over The Last Year?
ZVRA share price rose by 91.58% over the past 1 year
What Is Zevra Therapeutics 52-Week High & Low?
-
What Is Zevra Therapeutics’s 52-Week High Share Price?
Zevra Therapeutics has traded as high as $9.76 over the past 52 weeks -
What Is Zevra Therapeutics’s 52-Week Low Share Price?
Zevra Therapeutics has traded as low as $4.20 over the past 52 weeks
Zevra Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Zevra Therapeutics?
-
How Much Debt Does Zevra Therapeutics Have?
Total long term debt quarterly is $58.9M -
How Much Cash Does Zevra Therapeutics Have?
Cash and short term investments quarterly total is $89.4M -
What Is Zevra Therapeutics’s Book Value Per Share?
Book value per share is 1.31
Is Zevra Therapeutics Cash Flow Positive?
-
What Is ZVRA Cash Flow From Operations?
Cash flow from operations (TTM) is -$69.6M -
What Is Zevra Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $86.3M -
What Is Zevra Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$6.1M
Zevra Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
ZVRA return on invested capital is -85.03% -
What Is Zevra Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -56.14% -
What Is ZVRA Return On Equity?
ROE is a measure of profitability and is -159.89%
Zevra Therapeutics Earnings Date & Stock Price
-
What Is Zevra Therapeutics's Stock Price Today?
A single share of ZVRA can be purchased today for 9.33 -
What Is Zevra Therapeutics’s Stock Symbol?
Zevra Therapeutics trades on the nasdaq under the ticker symbol: ZVRA -
When Is Zevra Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Zevra Therapeutics is scheduled on March 28, 2025 -
When Is ZVRA's next ex-dividend date?
Zevra Therapeutics's next ex-dividend date is November 30, 2024 -
How To Buy Zevra Therapeutics Stock?
You can buy Zevra Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Zevra Therapeutics Competitors
-
Who Are Zevra Therapeutics's Competitors?
Below is a list of companies who compete with Zevra Therapeutics or are related in some way:
Zevra Therapeutics Dividend Yield
-
What Is ZVRA Dividend Yield?
Zevra Therapeutics’s dividend yield currently is 0% -
What Is Zevra Therapeutics’s Payout Ratio?
Zevra Therapeutics’s payout ratio is 0% -
When Did Zevra Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 30, 2024 -
What Is Zevra Therapeutics’s Dividend Per Share?
Zevra Therapeutics pays a dividend of $0.00 per share
Zevra Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -68.29% |
| Revenue: | 27.63% | -24.01% |
Analyst Recommendations
| Buy Recommendations: | 4 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 20.00 |
| Upside from Last Price: | 114.36% |